Clipper Young & Shirley Wong, ADCES 2022: New horizons in type 2 diabetes management and cardiorenal risk reduction: A pharmacotherapeutic update
Cardiorenal complications in people with type 2 diabetes illustrates a link between the heart and the kidneys, which can be exacerbated by other comorbidities, such as hypertension, dyslipidaemia, and obesity. In this touchENDOCRINOLOGY interview, Dr Clipper Young and Shirley Wong (Touro University California College of Osteopathic Medicine, Vallejo, CA, USA) firstly discuss diabetes management and ADA guidelines surrounding a multi-level approach for diabetes complication reduction. They also discuss the latest advances in insulin therapy and the latest clinical trials on cardiovascular effects of glucose-lowering agents, and advances in glucagon use for the treatment of hypoglycaemia.
The abstract entitled: ‘New Horizons in T2D Management and Cardiorenal Risk Reduction: A Pharmacotherapeutic Update‘ was presented at the Association of Diabetes Care & Education Specialists (ADCES) Annual Conference, 12-15 Aug, 2022.
- What factors increase cardiorenal risks in patients with type 2 diabetes (T2D)? (0:25)
- What have been the latest advances in insulin therapy? (1:20)
- Could you give us a brief overview of the latest clinical trials on cardiovascular effects of glucose-lowering agents? (3:47)
- How have the guidelines been updated to reflect these recent findings? (5:31)
- Can you tell us a little about the latest advances in glucagon use for the treatment of hypoglycaemia? (6:30)
Clipper Young was a consultant for Sanofi (October 2021); and has received grant support from Sutter Health.
Shirley Wong has nothing to disclose in relation to this video interview.
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Recorded as a highlight of ADCES 2022
Click here for more related content.
Share this Video
Related Videos In Diabetes
Chantal Mathieu: Research highlights from 2022 in diabetes
2022 saw the FDA approval of teplizumab to delay the onset of type 1 diabetes. In addition, there has also been evidence to suggest the effectivness of SGLT2 inhibitors in type 1 diabetes. We were delighted to speak with our editorial board member Prof. Chantal Mathieu (University Hospital Gasthuisberg Leuven, Leuven, Belgium) around this year’s research […]
José García-Tirado, DTM 2022: RocketAP in Practice: Results from Pilot and Feasibility Trials
In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) gives an overview of RocketAP and discusses how the RocketAP compares to the USS-Virginia system and also what the next steps in the clinical development of the Rocket AP will be. The abstract entitled: ‘RocketAP in Practice: Results from Pilot and Feasibility […]
José García-Tirado, DTM 2022: Challenges in the development of artificial pancreas systems
An artificial pancreas is a system made of three parts that work together to mimic how a healthy pancreas controls blood glucose in the body. In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) discusses the major challenges in the development of artificial pancreas systems. The abstract entitled: ‘RocketAP in Practice: Results from Pilot […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!